Gastric Cancer
Copyright ©2006 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Sep 14, 2006; 12(34): 5473-5478
Published online Sep 14, 2006. doi: 10.3748/wjg.v12.i34.5473
-765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia
Carina Pereira, Hugo Sousa, Paula Ferreira, Maria Fragoso, Luís Moreira-Dias, Carlos Lopes, Rui Medeiros, Mário Dinis-Ribeiro
Carina Pereira, Paula Ferreira, Molecular Oncology Group, Portuguese Institute of Oncology of Porto, Portugal
Maria Fragoso, Oncology Department, Portuguese Institute of Oncology of Porto, Portugal
Luís Moreira-Dias, Gastroenterology Department, Portuguese Institute of Oncology of Porto, Portugal
Hugo Sousa, Carlos Lopes, Rui Medeiros, Molecular Oncology Group, Portuguese Institute of Oncology of Porto, Portugal; and ICBAS, Abel Salazar Institute for the Biomedical Sciences, Porto, Portugal
Mário Dinis-Ribeiro, Gastroenterology Department, Portuguese Institute of Oncology of Porto, Portugal; and Cintesis / Faculty of Medicine University of Porto, Porto, Portugal
Supported by the Portuguese League Against Cancer (Liga Portuguesa Contra o Cancro-Núcleo Regional do Norte) and AstraZeneca Foundation
Correspondence to: Mário Dinis-Ribeiro, MD, PhD, Serviço de Gastrenterologia, Instituto Português de Oncologia do Porto FG EPE, Rua Dr. António Bernardino Almeida, 4200-072 Porto, Portugal. mario@med.up.pt
Telephone: +351-22-5084000-348 Fax: +351-22-5084001
Received: May 12, 2006
Revised: May 28, 2006
Accepted: June 16, 2006
Published online: September 14, 2006
Abstract

AIM: To investigate the relationship between the -765G > C COX-2 polymorphism and the development of different gastric lesions: atrophy or intestinal metaplasia and gastric adenocarcinoma.

METHODS: A cross-sectional study was performed involving 320 Portuguese individuals (210 without evidence of neoplastic disease, 73 patients with gastric adenocarcinomas and 37 with atrophy or intestinal metaplasia) using a PCR-RFLP method.

RESULTS: -765C allele was overrepresented in the patients with gastric adenocarcinoma (51%) when compared either with the control group (38%) or patients with atrophy or intestinal metaplasia (27%). Callele was found to be very common in our population (0.22), and a multivariate logistic regression analysis revealed nearly 3-fold increased risk for the progression to gastric adenocarcinoma in patients with atrophy or intestinal metaplasia carrying the -765C allele (OR = 2.67, 95% CI = 1.03-6.93; P = 0.04).

CONCLUSION: -765C carrier status should be considered as another susceptibility marker for gastric adenocarcinoma development in patients with atrophy or intestinal metaplasia.

Keywords: Gastric adenocarcinoma; Atrophy; Intestinal metaplasia; COX-2; Polymorphism; PCR-RFLP; Pharmacogenomic